WC
IRLA

Wexford Capital’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Wexford Capital’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7
Closed -$40K – 313
2020
Q4 		$40K Buy
+7
New +$62K 0.01% 245

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $31.9B AUM 28.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wexford Capital's IRLA Position: Q1 2021 in Review

Wexford Capital sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2021, closing a stake of 7 shares — an estimated $40K sold.

Wexford Capital first reported a position in IRLA in Q4 2020 and held it in 1 quarter. The position peaked at $40K in Q4 2020. 86 funds tracked by Wall St. Rank hold IRLA as of Q1 2021.

  • Wexford Capital reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 7 IRulya Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $40K.
  • Wexford Capital first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Wexford Capital's IRulya Therapeutics Inc. Common Stock position peaked at $40K in Q4 2020.
  • 86 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.